Barclays
FHTX icon

Barclays’s Foghorn Therapeutics FHTX Stock Holding History

Barclays’s Portfolio FHTX Stock Details FHTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$92.9K Sell
19,433
-43,757
-69% -$240K ﹤0.01% 4054
2025
Q4 		$341K Buy
63,190
+4,704
+8% +$21.3K ﹤0.01% 4067
2025
Q3 		$286K Sell
58,486
-12,328
-17% -$65.4K ﹤0.01% 4136
2025
Q2 		$333K Buy
70,814
+30,924
+78% +$129K ﹤0.01% 3988
2025
Q1 		$146K Sell
39,890
-11,719
-23% -$53.4K ﹤0.01% 4228
2024
Q4 		$244K Buy
51,609
+11,689
+29% +$85.2K ﹤0.01% 4215
2024
Q3 		$372K Buy
39,920
+26,228
+192% +$190K ﹤0.01% 3954
2024
Q2 		$78.7K Sell
13,692
-5,550
-29% -$33.1K ﹤0.01% 4022
2024
Q1 		$129K Sell
19,242
-13,662
-42% -$75.8K ﹤0.01% 4335
2023
Q4 		$212K Buy
32,904
+29,341
+823% +$127K ﹤0.01% 4392
2023
Q3 		$17.8K Sell
3,563
-508
-12% -$3.92K ﹤0.01% 4203
2023
Q2 		$28.7K Sell
4,071
-6,055
-60% -$42.3K ﹤0.01% 4054
2023
Q1 		$62.8K Buy
10,126
+4,729
+88% +$31K ﹤0.01% 4369
2022
Q4 		$34.4K Buy
5,397
+4,545
+533% +$34.3K ﹤0.01% 4673
2022
Q3 		$7K Sell
852
-156
-15% -$2.01K ﹤0.01% 4417
2022
Q2 		$14K Sell
1,008
-2,170
-68% -$28K ﹤0.01% 4516
2022
Q1 		$48K Buy
+3,178
New +$43.6K ﹤0.01% 4132

Other funds holding FHTX

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
EC
Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Barclays's FHTX Position: Q1 2026 in Review

Barclays reduced its Foghorn Therapeutics (FHTX) stake by 69% in Q1 2026, selling an estimated $240K and leaving 19,433 shares worth $92.9K. The position accounts for ﹤0.01% of the portfolio, ranked #4054.

Barclays first reported a position in FHTX in Q1 2022 and has held it in 17 quarters since. The position peaked at $372K in Q3 2024. 105 funds tracked by Wall St. Rank hold FHTX as of Q1 2026.

  • Barclays held 19,433 shares of Foghorn Therapeutics worth $92.9K as of Q1 2026.
  • Barclays sold 43,757 Foghorn Therapeutics shares in Q1 2026, an estimated $240K.
  • Foghorn Therapeutics made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #4054 holding.
  • Barclays first reported a position in Foghorn Therapeutics in Q1 2022 and has held it in 17 quarters since.
  • Barclays's Foghorn Therapeutics position peaked at $372K in Q3 2024.
  • 105 funds tracked by Wall St. Rank held Foghorn Therapeutics as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.